Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology Pharmaceutical Investing
Albert Labs signs Letter of Intent with iNGEN? CRO for First In-Human Clinical Studies Pharmaceutical Investing
Canadian Migraine Sufferers Have New Treatment Option - Health Canada Approves UBRELVY® Pharmaceutical Investing
BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com Pharmaceutical Investing
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Pharmaceutical Investing
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights Pharmaceutical Investing
LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer Life Science Investing
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences Pharmaceutical Investing
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Pharmaceutical Investing
Health Canada Approves Camzyos for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Pharmaceutical Investing
